RG
TEVA icon

Redmile Group’s Teva Pharmaceuticals TEVA Stock Holding History

Redmile Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,147,000
Closed -$49.3M – 95
2019
Q1 		$49.3M Buy
3,147,000
+1,318,100
+72% +$23.2M 1.44% 23
2018
Q4 		$28.2M Buy
+1,828,900
New +$37.5M 1.13% 31
2016
Q1 		– Sell
-938,139
Closed -$61.6M – 55
2015
Q4 		$61.6M Sell
938,139
-199,420
-18% -$12.3M 4.61% 8
2015
Q3 		$64.2M Buy
1,137,559
+170,200
+18% +$11M 4.87% 6
2015
Q2 		$57.2M Buy
967,359
+113,386
+13% +$6.99M 4.69% 5
2015
Q1 		$53.2M Buy
+853,973
New +$49.7M 4.78% 5

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group's TEVA Position: Q2 2019 in Review

Redmile Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 3,147,000 shares — an estimated $49.3M sold.

Redmile Group first reported a position in TEVA in Q1 2015 and held it in 6 quarters. The position peaked at $64.2M in Q3 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Redmile Group reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Redmile Group sold 3,147,000 Teva Pharmaceuticals shares in Q2 2019, an estimated $49.3M.
  • Redmile Group first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Redmile Group's Teva Pharmaceuticals position peaked at $64.2M in Q3 2015.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.